Q3 FY2025 · Presentation
20251009_Akero_conf_call_slides (2) · 8 pages
Read Novo Nordisk A/S Class B's results firsthand
Preview the first 2 pages of this presentation
Create a free account to start reading
Full documents are included with Professional